Serum LRG Levels as a Noninvasive Marker to Predict Histologic Remission in Ulcerative Colitis Patients

What this Trial Is About

Researchers are studying the serum leucine-rich 2-glycoprotein LRG level to see if it can predict histologic remission in patients with ulcerative colitis UC. The study aims to clarify the specific LRG level that indicates histologic remission, which may serve as a noninvasive biomarker for monitoring disease activity in UC. This observational research is conducted by Showa Inan General Hospital. Participants with UC will have their serum LRG levels measured using an enzyme-linked immunosorbent assay. Colonoscopy with histologic examination is performed when histologic remission is predicted, regardless of symptoms or serum LRG values. Clinical remission is determined by a partial Mayo score of 0 or 1, endoscopic remission by a Mayo endoscopic subscore of 0, and histologic remission by a Geboes score less than 2. During the study, participants will undergo colonoscopies with histology to confirm remission status. The diagnostic ability of LRG to predict histologic remission will be analyzed using receiver operating characteristic ROC curves. The primary outcome is histologic remission of UC assessed within one week, and endoscopic remission is also evaluated. The study runs until December 2027 and includes patients aged 20 to 90 years.

Association Between LRG and Histologic Remission in Ulcerative Colitis